Covid-19 roundup: AlloVir snags IND approval for potential T cell therapy; Sanofi and GSK strike 300 million-dose deal with the EU
After snagging IND approval for its off-the-shelf virus-specific T cell Covid-19 therapy, AlloVir is now racing toward a proof-of-concept study.
The candidate, ALVR109, is designed to halt the progression of Covid-19 by destroying SARS-CoV-2-infected cells.
In March, AlloVir expanded its partnership with the Baylor College of Medicine to develop treatments that restore T-cell immunity in immune-compromised patients. In addition to Covid-19, the program pursues SARS classic, MERS and four other coronaviruses.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,400+ biopharma pros reading Endpoints daily — and it's free.